NO854392L - Fremgangsmaate ved fremstilling av 3-amino-2,3-dihydro-1-benzoxepin-derivater. - Google Patents
Fremgangsmaate ved fremstilling av 3-amino-2,3-dihydro-1-benzoxepin-derivater.Info
- Publication number
- NO854392L NO854392L NO854392A NO854392A NO854392L NO 854392 L NO854392 L NO 854392L NO 854392 A NO854392 A NO 854392A NO 854392 A NO854392 A NO 854392A NO 854392 L NO854392 L NO 854392L
- Authority
- NO
- Norway
- Prior art keywords
- lower alkyl
- denotes hydrogen
- group
- compounds
- halogen
- Prior art date
Links
- GOQVPHDULWKVKE-UHFFFAOYSA-N 2,3-dihydro-1-benzoxepin-3-amine Chemical class C1=CC(N)COC2=CC=CC=C21 GOQVPHDULWKVKE-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 44
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 38
- 239000001257 hydrogen Substances 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 32
- 150000002367 halogens Chemical class 0.000 claims abstract description 17
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 16
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 16
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 7
- 125000003277 amino group Chemical group 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- DKCMLUGVNDXSDD-UHFFFAOYSA-N n-methyl-2,3-dihydro-1-benzoxepin-3-amine Chemical compound C1=CC(NC)COC2=CC=CC=C21 DKCMLUGVNDXSDD-UHFFFAOYSA-N 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000007858 starting material Substances 0.000 claims 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 7
- 230000001430 anti-depressive effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229960005333 tetrabenazine Drugs 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 6
- MUZPHQWEBODJTH-UHFFFAOYSA-N 3-amino-2,3,4,5-tetrahydro-1-benzoxepin-5-ol Chemical class OC1CC(N)COC2=CC=CC=C21 MUZPHQWEBODJTH-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- -1 for example Chemical group 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002631 hypothermal effect Effects 0.000 description 3
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 3
- IAYBRKMKVGEUDZ-UHFFFAOYSA-N n-methyl-2,3-dihydro-1-benzoxepin-3-amine;hydrochloride Chemical compound Cl.C1=CC(NC)COC2=CC=CC=C21 IAYBRKMKVGEUDZ-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- IJHLJYUCCGGECZ-UHFFFAOYSA-N 1-benzoxepin-5-ol;hydrochloride Chemical compound Cl.OC1=CC=COC2=CC=CC=C12 IJHLJYUCCGGECZ-UHFFFAOYSA-N 0.000 description 1
- XLHBVMMNULTPHQ-UHFFFAOYSA-N 3-(butylamino)-2,3,4,5-tetrahydro-1-benzoxepin-5-ol;hydrochloride Chemical compound Cl.OC1CC(NCCCC)COC2=CC=CC=C21 XLHBVMMNULTPHQ-UHFFFAOYSA-N 0.000 description 1
- JWUPWOYNGNTOKD-UHFFFAOYSA-N 3-(methylamino)-2,3,4,5-tetrahydro-1-benzoxepin-5-ol Chemical compound OC1CC(NC)COC2=CC=CC=C21 JWUPWOYNGNTOKD-UHFFFAOYSA-N 0.000 description 1
- WCDHGUIVSKAJDW-UHFFFAOYSA-N 3-(methylamino)-2,3,4,5-tetrahydro-1-benzoxepin-5-ol;hydrochloride Chemical compound Cl.OC1CC(NC)COC2=CC=CC=C21 WCDHGUIVSKAJDW-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- KADXIUUHHDWJLH-UHFFFAOYSA-N n,7,8-trimethyl-2,3-dihydro-1-benzoxepin-3-amine Chemical compound C1=CC(NC)COC2=CC(C)=C(C)C=C21 KADXIUUHHDWJLH-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IKGMYJIGCYUOHU-UHFFFAOYSA-N n-butyl-2,3-dihydro-1-benzoxepin-3-amine;hydrochloride Chemical compound Cl.C1=CC(NCCCC)COC2=CC=CC=C21 IKGMYJIGCYUOHU-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19843440296 DE3440296A1 (de) | 1984-11-05 | 1984-11-05 | 3-amino-2,3-dihydro-1-benzoxepin-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO854392L true NO854392L (no) | 1986-05-06 |
Family
ID=6249484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO854392A NO854392L (no) | 1984-11-05 | 1985-11-04 | Fremgangsmaate ved fremstilling av 3-amino-2,3-dihydro-1-benzoxepin-derivater. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4672062A (ca) |
| EP (1) | EP0180889B1 (ca) |
| JP (1) | JPH0641461B2 (ca) |
| AT (1) | ATE43839T1 (ca) |
| AU (1) | AU579416B2 (ca) |
| CA (1) | CA1254893A (ca) |
| DD (1) | DD238049A5 (ca) |
| DE (2) | DE3440296A1 (ca) |
| DK (1) | DK506885A (ca) |
| ES (1) | ES8606325A1 (ca) |
| FI (1) | FI854343L (ca) |
| GR (1) | GR852638B (ca) |
| HU (1) | HU194205B (ca) |
| IL (1) | IL76936A (ca) |
| NO (1) | NO854392L (ca) |
| NZ (1) | NZ214066A (ca) |
| PH (1) | PH22384A (ca) |
| PT (1) | PT81422B (ca) |
| ZA (1) | ZA858376B (ca) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2169134B (en) * | 1984-11-16 | 1988-11-16 | Canon Kk | Multibeam emitting device |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1593760A1 (de) * | 1967-02-01 | 1972-06-08 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung neuer Benz-epinderivate |
| DE2931399A1 (de) * | 1979-08-02 | 1981-02-26 | Kali Chemie Pharma Gmbh | Neue 3-amino-1-benzoxepin-derivate und ihre salze, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| DE2931398A1 (de) * | 1979-08-02 | 1981-02-26 | Kali Chemie Pharma Gmbh | Neue 1-benzoxepin-5(2h)-on-derivate und ihre salze, verfahren und zwischenprodukte zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| DE3440295A1 (de) * | 1984-11-05 | 1986-05-15 | Kali-Chemie Pharma Gmbh, 3000 Hannover | Verfahren zur diastereoselektiven reduktion von 3-amino-1-benzoxepin-5(2h)-onen |
-
1984
- 1984-11-05 DE DE19843440296 patent/DE3440296A1/de not_active Withdrawn
-
1985
- 1985-10-28 DE DE8585113699T patent/DE3570877D1/de not_active Expired
- 1985-10-28 PH PH32985A patent/PH22384A/en unknown
- 1985-10-28 AT AT85113699T patent/ATE43839T1/de not_active IP Right Cessation
- 1985-10-28 EP EP85113699A patent/EP0180889B1/de not_active Expired
- 1985-10-31 PT PT81422A patent/PT81422B/pt unknown
- 1985-10-31 ZA ZA858376A patent/ZA858376B/xx unknown
- 1985-11-01 DD DD85282372A patent/DD238049A5/de unknown
- 1985-11-01 GR GR852638A patent/GR852638B/el unknown
- 1985-11-01 HU HU854192A patent/HU194205B/hu not_active IP Right Cessation
- 1985-11-04 NO NO854392A patent/NO854392L/no unknown
- 1985-11-04 ES ES548497A patent/ES8606325A1/es not_active Expired
- 1985-11-04 US US06/794,761 patent/US4672062A/en not_active Expired - Fee Related
- 1985-11-04 AU AU49346/85A patent/AU579416B2/en not_active Ceased
- 1985-11-04 DK DK506885A patent/DK506885A/da not_active Application Discontinuation
- 1985-11-04 IL IL76936A patent/IL76936A/xx unknown
- 1985-11-05 FI FI854343A patent/FI854343L/fi not_active IP Right Cessation
- 1985-11-05 NZ NZ214066A patent/NZ214066A/en unknown
- 1985-11-05 JP JP60246463A patent/JPH0641461B2/ja not_active Expired - Lifetime
- 1985-11-05 CA CA000494616A patent/CA1254893A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FI854343A7 (fi) | 1986-05-06 |
| ES548497A0 (es) | 1986-03-16 |
| PT81422B (en) | 1987-07-31 |
| ATE43839T1 (de) | 1989-06-15 |
| ES8606325A1 (es) | 1986-03-16 |
| EP0180889B1 (de) | 1989-06-07 |
| DD238049A5 (de) | 1986-08-06 |
| US4672062A (en) | 1987-06-09 |
| EP0180889A3 (en) | 1987-08-19 |
| IL76936A0 (en) | 1986-04-29 |
| ZA858376B (en) | 1986-07-30 |
| JPS61178979A (ja) | 1986-08-11 |
| IL76936A (en) | 1989-01-31 |
| DE3570877D1 (en) | 1989-07-13 |
| EP0180889A2 (de) | 1986-05-14 |
| PH22384A (en) | 1988-08-12 |
| DK506885D0 (da) | 1985-11-04 |
| NZ214066A (en) | 1988-04-29 |
| GR852638B (ca) | 1986-03-04 |
| AU579416B2 (en) | 1988-11-24 |
| HU194205B (en) | 1988-01-28 |
| DK506885A (da) | 1986-05-06 |
| AU4934685A (en) | 1986-05-15 |
| FI854343A0 (fi) | 1985-11-05 |
| HUT39173A (en) | 1986-08-28 |
| JPH0641461B2 (ja) | 1994-06-01 |
| DE3440296A1 (de) | 1986-05-15 |
| PT81422A (en) | 1985-11-01 |
| FI854343L (fi) | 1986-05-06 |
| CA1254893A (en) | 1989-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4727925B2 (ja) | 統合失調症およびうつ病等の疾患を処置するためのフェノキシピペリジン | |
| KR20040079987A (ko) | 클로피도그렐 히드로클로라이드의 다형체 및 이의 항혈전화합물로서의 용도 | |
| KR20100087300A (ko) | 글리코겐 포스포릴라아제 억제제 화합물 및 이의 약학적 조성물 | |
| JP2010505747A (ja) | Ａ２ａアデノシンレセプタの選択的アンタゴニスト | |
| US4518712A (en) | Piperazine derivative and analgesic composition containing the same | |
| EP1572646A1 (de) | N-(indolethyl-)cycloamin-verbindungen | |
| BG64390B1 (bg) | Карбоцикличен нуклеозиден хемисулфат и неговото използване при лечението на вирусни инфекции | |
| RU2343152C2 (ru) | Замещенные дикетопиперазины и их использование в качестве антагонистов окситоцина | |
| EP0163537A1 (en) | 1-Propanone derivatives and pharmaceutical compositions containing same | |
| LU86421A1 (fr) | Derives de piperazine 1,4-disubstitues,composition pharmaceutique les contenant;leur procede d'obtention | |
| CN107793350B (zh) | 芳乙基哌啶基衍生物及其治疗精神分裂症的应用 | |
| SK11795A3 (en) | Treatment containing 3-phenylsulfonyl-3,7-diazobicyclo /3,3,1/ nonane compounds | |
| HU198055B (en) | Process for producing n-benzofuroquinolizinyl sulfonamide derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
| MC1562A1 (fr) | Phenothiazines,leur procede de preparation et produits en contenant | |
| CA1278572C (en) | Ameliorant of cerebral circulation and metabolism | |
| KR100503518B1 (ko) | 2-(4-알킬-1-피페라지닐)-벤즈알데하이드 및 -벤질리데닐화합물의 제조 방법 | |
| JPH06116273A (ja) | 三環系化合物 | |
| JPH10237028A (ja) | Ｎｏｓ阻害作用を有する芳香族アミン誘導体 | |
| JPS61178979A (ja) | ３−アミノ−２，３−ジヒドロ−１−ベンゾキセピン化合物、その製造法及び該化合物を含有する、抗抑圧作用を有する医薬調剤 | |
| US3686217A (en) | 2-aryl-2,3,4,5-tetrahydro-1,4-benzoxazepines | |
| JPH08109177A (ja) | シクロアルキルアルキルアミン誘導体およびその用途 | |
| US4176230A (en) | 5-(6-Alkylindol-3-ylmethylene)-1,3-dimethyl-2-(methylimino)-4-imidazolidinones | |
| US3919311A (en) | 3A,12B-Dihydro-8H-dibenzo{8 3,4,6,7{9 cyclohept{8 1,2-d{9 oxazol-8-ones and process for their preparation | |
| GB2265369A (en) | 2-(substituted imino)-thiazolidines and process for the preparation thereof | |
| JPH04356466A (ja) | 新規キノリン誘導体及びそれを有効成分として含有する制癌剤効果増強剤 |